| Authors: |
Tan WC; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada wan.tan@hli.ubc.ca., Bourbeau J; Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, McGill University, Montréal, QC, Canada., Nadeau G; Respiratory Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada., Wang W; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Barnes N; William Harvey Institute, Bart's and the London School of Medicine and Dentistry, and Respiratory Therapy Area, GlaxoSmithKline plc, London, UK., Landis SH; Real World Evidence and Epidemiology, GlaxoSmithKline plc, Uxbridge, UK., Kirby M; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.; Dept of Physics, Ryerson University, Toronto, ON, Canada., Hogg JC; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Sin DD; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.; A list of members of the COLD/CanCOLD Collaborative Research Group can be found in the acknowledgements section. |
